Kintiga, formerly known as MAP Patient Access, AxTalis & SKC, is an emerging player in the pharmaceutical and biotechnology management consultancy space. Founded in 2024 and headquartered in the United Kingdom, this independent specialist firm is strategically positioned to offer unique management consultancy capabilities in Europe’s intricate medical landscape.
The company addresses the multifaceted challenges of maximising pharmaceutical product value and ensuring patient access to critical medicines. It leverages its robust consultancy products and services along the development-to-commercialisation path. Additionally, Kintiga offers an exclusive online membership platform that connects clients to experts, a valuable database, and a suite of tools tailored for the pharmaceutical sector.
With no prior disclosed investments, Kintiga potentially represents a compelling opportunity for investors seeking to penetrate the European pharma consultancy market, amplified by its slogan, "Where energy meets experience."